Stakeholders Urge Labor Department to Finalize PBM Transparency Rule

Why It Matters

Greater PBM transparency could expose hidden profit margins, helping employers control drug costs and prompting more competitive pricing in the pharmaceutical supply chain.

Key Takeaways

• Stakeholders submitted ~560 comments urging DOL to finalize PBM rule quickly
• Rule mandates dollar‑level disclosure of rebates, spread‑pricing, and other payments
• PBMs argue the rule adds administrative burden and may hurt competition
• Comments request extending requirements to fully‑insured plans and GPOs
• Bipartisan coalition of attorneys general backs enforcement of the rule

Pulse Analysis

The Department of Labor’s pending pharmacy‑benefit‑manager transparency rule has become a flashpoint between employers seeking cost clarity and PBMs defending proprietary pricing models. Since its January rollout, the proposal has attracted roughly 560 public comments, with a coalition of employers, patient advocates, and state officials urging rapid finalization. By compelling PBMs to reveal exact dollar amounts for rebates, spread‑pricing, and other compensation, the rule promises to lift the veil on a market that has long been shrouded in opaque contracts, giving plan fiduciaries concrete data for negotiating better terms.

PBMs, led by the industry lobby the Pharmaceutical Care Management Association, counter that the rule duplicates existing disclosure obligations and could strain smaller players, potentially reducing competition. Critics also note gaps: the current draft applies only to self‑insured group plans, leaving fully‑insured coverage— a sizable market segment—unaddressed. Commenters have urged the DOL to broaden the scope to include all PBM‑controlled entities, such as group‑purchasing organizations, and to align the rule with the transparency mandates of the Consolidated Appropriations Act of 2026. Aligning these frameworks could prevent fragmented reporting and ensure consistent data across federal and private sectors.

If finalized, the rule could reshape the pharmaceutical supply chain by forcing the “Big Three” PBMs—Cigna’s Express Scripts, CVS Caremark and UnitedHealth’s Optum Rx—to disclose the financial mechanics that drive prescription‑drug pricing. Greater visibility may spur competitive bidding, pressure profit margins, and empower employers to audit PBM performance more rigorously. However, transparency alone may not dismantle the market concentration that gives these giants 80% of U.S. prescriptions, suggesting that legislative or antitrust actions could follow. The timing, ahead of the 2026 midterms, adds political urgency to an issue that directly impacts workers’ out‑of‑pocket drug costs.